NCT00803283 - A Study to Compare Safety and Efficacy of Osmotic Release Oral Syytem (OROS) Hydromorphone Hydrochloride (HCl) With Morphine Sustain Release (SR) in Participants With Cancer Pain | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions

Cancer Pain

Interventions

DRUG

Hydromprphone Hydrochloride (HCl) OROS

Participants will receive hydromorphone HCl OROS 8 milligram (mg) every 24 hours, for 3 to 14 days of titration phase. Hydromorphone HCl OROS will be continued as per Investigator's discretion for next 14 days of maintenance phase.

DRUG

Morphine Sustain Release (SR)

Participants will receive morphine SR 8 mg every24 hours, for 3 to14 days of titration phase. Morphine SR will be continued as per Investigator's discretion for next 14 days of maintenance phase.